<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02047604</url>
  </required_header>
  <id_info>
    <org_study_id>C2013-0302</org_study_id>
    <secondary_id>2013-003719-23</secondary_id>
    <nct_id>NCT02047604</nct_id>
  </id_info>
  <brief_title>(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch Health Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch Health Americas, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of&#xD;
      Escalating Doses of SAN-300 in Patients with Active Rheumatoid Arthritis with Inadequate&#xD;
      Response to Disease-Modifying Anti-rheumatic Drug(s).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2013</start_date>
  <completion_date type="Actual">March 23, 2017</completion_date>
  <primary_completion_date type="Actual">February 23, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>10 weeks</time_frame>
    <description>Adverse events data are collected during a 10-week period, which includes 6 weeks of treatment and 4 weeks of follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Activity Score With 28-joint Count Using C-reactive Protein (DAS28-CRP)</measure>
    <time_frame>Baseline, End of Treatment Visit (Week 7)</time_frame>
    <description>DAS28-CRP= 0.56 x sqrt(TJC28) x sqrt(SJC28) + 0.36 x ln(CRP+1) +0.014 x VAS +0.96 Where TJC28: The number of tender joints (0-28). SJC28: The number of swollen joints (0-28). CRP: The C-Reactive Protein level (in mg/l). VAS General Health Assessment (from 0=best to 100=worst). ln=natural log. sqrt = square root. Higher scores indicate worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With American College of Rheumatology 20 (ACR20) Response.</measure>
    <time_frame>End of Treatment Visit (Week 7)</time_frame>
    <description>A participant is considered to have an ACR20 response if there is an improvement of 20% in all of the following:&#xD;
Swollen joint count (66 joints)&#xD;
Tender joint count (68 joints) and&#xD;
At least three of the following five assessments:&#xD;
Patient's assessment of pain&#xD;
Patient's global assessment of disease activity&#xD;
Physician's global assessment of disease activity&#xD;
Patient's assessment of physical function, as measured by the HAQ-DI&#xD;
CRP</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change From Baseline in the Health Assessment Questionnaire-Disease Index (HAQ-DI)</measure>
    <time_frame>Baseline, End of Treatment Visit (Week 7)</time_frame>
    <description>HAQ assesses the degree of difficulty a participant has had in accomplishing tasks in eight functional areas, over the previous week.&#xD;
dressing and grooming,&#xD;
rising,&#xD;
eating,&#xD;
walking,&#xD;
hygiene,&#xD;
reach,&#xD;
grip,&#xD;
common daily activities. For each of these categories, participants report amount of difficulty they have in performing two or three specific activities. There are four possible responses for the HAQ questions: without ANY difficulty&#xD;
(0), with SOME difficulty (1), with MUCH difficulty (2) and UNABLE to do (3). Scores for each of the eight categories are calculated. HAQ is calculated by adjusting the score for each of these categories, if necessary, based upon the patient's use of an aid, device, or assistance for that category, totaling the sum of the category scores and dividing by the number of categories answered. HAQ can range from 0 to 3. Higher scores (greater level of difficulty) indicate worse outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Bone Erosion Detected Using Magnetic Resonance Imaging (MRI) Findings of the Hand and Wrist - Change From Baseline</measure>
    <time_frame>Baseline, End of Treatment Visit (Week 7)</time_frame>
    <description>Bone Erosion detected by MRI of hand/wrist was scored using the Outcome Measures in Rheumatology Clinical Trials (OMERACT) RA MRI scoring (RAMRIS) system. Bone erosion was scored 0-10, according to the proportion (in increments of 10%) of erosion of articular bone: 0: 0%, 1: 1%-10%, 2: 11%-20%, ……..10: 91%-100%. Higher scores (more erosion) indicate worse outcome.</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Cohort A - SAN-300 0.5 mg/kg QW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAN-300 0.5 mg/kg subcutaneous once weekly for six weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B - SAN-300 1.0 mg/kg QW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAN-300 1.0 mg/kg subcutaneous once weekly for six weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C - SAN-300 2.0 mg/kg QOW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAN-300 2.0 mg/kg subcutaneous every other week for six weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D - SAN-300 4.0 mg/kg QOW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAN-300 4.0 mg/kg subcutaneous every other week for six weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort E - SAN-300 4.0 mg/kg QW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAN-300 4.0 mg/kg subcutaneous every other week for six weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAN-300 0.5 mg/kg QW</intervention_name>
    <arm_group_label>Cohort A - SAN-300 0.5 mg/kg QW</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAN-300 1.0 mg/kg QW</intervention_name>
    <arm_group_label>Cohort B - SAN-300 1.0 mg/kg QW</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAN-300 2.0 mg/kg QOW</intervention_name>
    <arm_group_label>Cohort C - SAN-300 2.0 mg/kg QOW</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAN-300 4.0 mg/kg QOW</intervention_name>
    <arm_group_label>Cohort D - SAN-300 4.0 mg/kg QOW</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAN-300 4.0 mg/kg QW</intervention_name>
    <arm_group_label>Cohort E - SAN-300 4.0 mg/kg QW</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosed with RA for ≥ 6 months according to American College of Rheumatology&#xD;
             (ACR)/European League Against Rheumatism (EULAR) Classification Criteria 2010&#xD;
&#xD;
          2. 18 to 75 years of age, inclusive, at the time of informed consent&#xD;
&#xD;
          3. Swollen joint count of ≥ 6 (66-joint count) and tender joint count of ≥ 6 (68-joint&#xD;
             count) at Screening and randomization&#xD;
&#xD;
          4. Inadequate response to therapy or discontinuation of therapy because of unacceptable&#xD;
             toxicity from at least one prior traditional or biologic disease-modifying&#xD;
             anti-rheumatic drug (DMARD)&#xD;
&#xD;
          5. Stable dose of methotrexate (≥ 15 mg/week and ≤ 25 mg/week) for ≥ 6 weeks before&#xD;
             randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Functional Class IV as defined by ACR classification of functional status in RA&#xD;
&#xD;
          2. History of significant systemic involvement secondary to RA (e.g., vasculitis,&#xD;
             pulmonary fibrosis, or Felty's syndrome)&#xD;
&#xD;
          3. History of malignancy or carcinoma in situ within the 5 years before Screening or any&#xD;
             history of melanoma. Patients with history of excised or adequately treated&#xD;
             non-melanoma skin cancer are eligible&#xD;
&#xD;
          4. Evidence of clinically significant uncontrolled concurrent diseases such as&#xD;
             cardiovascular, endocrinologic, hematologic, hepatic, immunologic, metabolic,&#xD;
             urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major&#xD;
             diseases&#xD;
&#xD;
          5. History of recurrent clinically significant infections&#xD;
&#xD;
          6. Current active infection or serious local infection (e.g., cellulitis, abscess) or&#xD;
             systemic infection (e.g., pneumonia, septicemia) within 3 months before randomization&#xD;
&#xD;
          7. History of severe allergic or anaphylactic reactions to other biologic agents&#xD;
&#xD;
          8. History of allergies to murine protein&#xD;
&#xD;
          9. Surgery within 3 months before randomization (other than minor cosmetic surgery or&#xD;
             minor dental procedures) or plans for a surgical procedure during the Treatment Period&#xD;
             or Follow-up Period&#xD;
&#xD;
         10. History of tuberculosis or latent infection currently undergoing treatment&#xD;
&#xD;
         11. History of malaria&#xD;
&#xD;
         12. Treatment regimen with prednisone that is either over 10 mg/day (or equivalent dose of&#xD;
             another corticosteroid) or is not taken at a stable dose of ≤ 10 mg/day for at least 4&#xD;
             weeks before randomization&#xD;
&#xD;
         13. Intra-articular corticosteroid injection(s) within 4 weeks before randomization&#xD;
&#xD;
         14. Any live immunization/vaccination, including against Herpes zoster, within 4 weeks&#xD;
             before randomization. Live vaccinations must also be avoided throughout the study&#xD;
&#xD;
         15. Abnormal laboratory value at Screening or Day -1 considered clinically significant&#xD;
&#xD;
         16. Positive for hepatitis C virus (HCV) antibody or hepatitis B surface antigen (HBsAg)&#xD;
&#xD;
         17. Positive for human immunodeficiency virus (HIV) antibody&#xD;
&#xD;
         18. History of tuberculosis or positive QuantiFERON®-TB Gold test (QFT)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 1012</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 1004</name>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <zip>92020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 1008</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 1011</name>
      <address>
        <city>San Leandro</city>
        <state>California</state>
        <zip>94578</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 1013</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 1003</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 1017</name>
      <address>
        <city>Florissant</city>
        <state>Missouri</state>
        <zip>63031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 1009</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 1019</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 1014</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 1006</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santarus Clinical Investigational Site 1001</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 22, 2014</study_first_submitted>
  <study_first_submitted_qc>January 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2014</study_first_posted>
  <results_first_submitted>April 5, 2018</results_first_submitted>
  <results_first_submitted_qc>June 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 21, 2021</results_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 2a multiple ascending dose, Anti-Very Late Antigen-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 28, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT02047604/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT02047604/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort A - SAN-300 0.5 mg/kg QW</title>
          <description>SAN-300 0.5 mg/kg subcutaneous once weekly for six weeks</description>
        </group>
        <group group_id="P2">
          <title>Cohort B - SAN-300 1.0 mg/kg QW</title>
          <description>SAN-300 1.0 mg/kg subcutaneous once weekly for six weeks</description>
        </group>
        <group group_id="P3">
          <title>Cohort C - SAN-300 2.0 mg/kg QOW</title>
          <description>SAN-300 2.0 mg/kg subcutaneous every other week for six weeks</description>
        </group>
        <group group_id="P4">
          <title>Cohort D - SAN-300 4.0 mg/kg QOW</title>
          <description>SAN-300 4.0 mg/kg subcutaneous once every other week for six weeks</description>
        </group>
        <group group_id="P5">
          <title>Cohort E - SAN-300 4.0 mg/kg QW</title>
          <description>SAN-300 4.0 mg/kg subcutaneous every week for six weeks</description>
        </group>
        <group group_id="P6">
          <title>Placebo</title>
          <description>Placebo dosing</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort A - SAN-300 0.5 mg/kg QW</title>
          <description>SAN-300 0.5 mg/kg subcutaneous once weekly for six weeks</description>
        </group>
        <group group_id="B2">
          <title>Cohort B - SAN-300 1.0 mg/kg QW</title>
          <description>SAN-300 1.0 mg/kg subcutaneous once weekly for six weeks</description>
        </group>
        <group group_id="B3">
          <title>Cohort C - SAN-300 2.0 mg/kg QOW</title>
          <description>SAN-300 2.0 mg/kg subcutaneous every other week for six weeks</description>
        </group>
        <group group_id="B4">
          <title>Cohort D - SAN-300 4.0 mg/kg QOW</title>
          <description>SAN-300 4.0 mg/kg subcutaneous every other week for six weeks</description>
        </group>
        <group group_id="B5">
          <title>Cohort E - SAN-300 4.0 mg/kg QW</title>
          <description>SAN-300 4.0 mg/kg subcutaneous once weekly for six weeks</description>
        </group>
        <group group_id="B6">
          <title>Placebo</title>
          <description>Placebo dosing</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="10"/>
            <count group_id="B7" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.2" spread="2.82"/>
                    <measurement group_id="B2" value="60.9" spread="1.65"/>
                    <measurement group_id="B3" value="59.2" spread="4.87"/>
                    <measurement group_id="B4" value="49.0" spread="6.59"/>
                    <measurement group_id="B5" value="55.5" spread="4.42"/>
                    <measurement group_id="B6" value="57.5" spread="2.85"/>
                    <measurement group_id="B7" value="56.6" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Adverse events data are collected during a 10-week period, which includes 6 weeks of treatment and 4 weeks of follow-up.</description>
        <time_frame>10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort A - SAN-300 0.5 mg/kg QW</title>
            <description>SAN-300 0.5 mg/kg subcutaneous once weekly for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Cohort B - SAN-300 1.0 mg/kg QW</title>
            <description>SAN-300 1.0 mg/kg subcutaneous once weekly for six weeks</description>
          </group>
          <group group_id="O3">
            <title>Cohort C - SAN-300 2.0 mg/kg QOW</title>
            <description>SAN-300 2.0 mg/kg subcutaneous every other week for six weeks</description>
          </group>
          <group group_id="O4">
            <title>Cohort D - SAN-300 4.0 mg/kg QOW</title>
            <description>SAN-300 4.0 mg/kg subcutaneous once every other week for six weeks</description>
          </group>
          <group group_id="O5">
            <title>Cohort E - SAN-300 4.0 mg/kg QW</title>
            <description>SAN-300 4.0 mg/kg subcutaneous every week for six weeks</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo dosing</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Adverse events data are collected during a 10-week period, which includes 6 weeks of treatment and 4 weeks of follow-up.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Activity Score With 28-joint Count Using C-reactive Protein (DAS28-CRP)</title>
        <description>DAS28-CRP= 0.56 x sqrt(TJC28) x sqrt(SJC28) + 0.36 x ln(CRP+1) +0.014 x VAS +0.96 Where TJC28: The number of tender joints (0-28). SJC28: The number of swollen joints (0-28). CRP: The C-Reactive Protein level (in mg/l). VAS General Health Assessment (from 0=best to 100=worst). ln=natural log. sqrt = square root. Higher scores indicate worse outcome.</description>
        <time_frame>Baseline, End of Treatment Visit (Week 7)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort A - SAN-300 0.5 mg/kg QW</title>
            <description>SAN-300 0.5 mg/kg subcutaneous once weekly for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Cohort B - SAN-300 1.0 mg/kg QW</title>
            <description>SAN-300 1.0 mg/kg subcutaneous once weekly for six weeks</description>
          </group>
          <group group_id="O3">
            <title>Cohort C - SAN-300 2.0 mg/kg QOW</title>
            <description>SAN-300 2.0 mg/kg subcutaneous every other week for six weeks</description>
          </group>
          <group group_id="O4">
            <title>Cohort D - SAN-300 4.0 mg/kg QOW</title>
            <description>SAN-300 4.0 mg/kg subcutaneous once every other week for six weeks</description>
          </group>
          <group group_id="O5">
            <title>Cohort E - SAN-300 4.0 mg/kg QW</title>
            <description>SAN-300 4.0 mg/kg subcutaneous every week for six weeks</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo dosing</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Activity Score With 28-joint Count Using C-reactive Protein (DAS28-CRP)</title>
          <description>DAS28-CRP= 0.56 x sqrt(TJC28) x sqrt(SJC28) + 0.36 x ln(CRP+1) +0.014 x VAS +0.96 Where TJC28: The number of tender joints (0-28). SJC28: The number of swollen joints (0-28). CRP: The C-Reactive Protein level (in mg/l). VAS General Health Assessment (from 0=best to 100=worst). ln=natural log. sqrt = square root. Higher scores indicate worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.433" spread="1.2736"/>
                    <measurement group_id="O2" value="-3.663" spread="0.9716"/>
                    <measurement group_id="O3" value="-2.002" spread="0.8276"/>
                    <measurement group_id="O4" value="-3.818" spread="1.9164"/>
                    <measurement group_id="O5" value="-2.928" spread="1.9874"/>
                    <measurement group_id="O6" value="-3.028" spread="1.2505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With American College of Rheumatology 20 (ACR20) Response.</title>
        <description>A participant is considered to have an ACR20 response if there is an improvement of 20% in all of the following:&#xD;
Swollen joint count (66 joints)&#xD;
Tender joint count (68 joints) and&#xD;
At least three of the following five assessments:&#xD;
Patient's assessment of pain&#xD;
Patient's global assessment of disease activity&#xD;
Physician's global assessment of disease activity&#xD;
Patient's assessment of physical function, as measured by the HAQ-DI&#xD;
CRP</description>
        <time_frame>End of Treatment Visit (Week 7)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort A - SAN-300 0.5 mg/kg QW</title>
            <description>SAN-300 0.5 mg/kg subcutaneous once weekly for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Cohort B - SAN-300 1.0 mg/kg QW</title>
            <description>SAN-300 1.0 mg/kg subcutaneous once weekly for six weeks</description>
          </group>
          <group group_id="O3">
            <title>Cohort C - SAN-300 2.0 mg/kg QOW</title>
            <description>SAN-300 2.0 mg/kg subcutaneous every other week for six weeks</description>
          </group>
          <group group_id="O4">
            <title>Cohort D - SAN-300 4.0 mg/kg QOW</title>
            <description>SAN-300 4.0 mg/kg subcutaneous once every other week for six weeks</description>
          </group>
          <group group_id="O5">
            <title>Cohort E - SAN-300 4.0 mg/kg QW</title>
            <description>SAN-300 4.0 mg/kg subcutaneous every week for six weeks</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo dosing</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With American College of Rheumatology 20 (ACR20) Response.</title>
          <description>A participant is considered to have an ACR20 response if there is an improvement of 20% in all of the following:&#xD;
Swollen joint count (66 joints)&#xD;
Tender joint count (68 joints) and&#xD;
At least three of the following five assessments:&#xD;
Patient's assessment of pain&#xD;
Patient's global assessment of disease activity&#xD;
Physician's global assessment of disease activity&#xD;
Patient's assessment of physical function, as measured by the HAQ-DI&#xD;
CRP</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in the Health Assessment Questionnaire-Disease Index (HAQ-DI)</title>
        <description>HAQ assesses the degree of difficulty a participant has had in accomplishing tasks in eight functional areas, over the previous week.&#xD;
dressing and grooming,&#xD;
rising,&#xD;
eating,&#xD;
walking,&#xD;
hygiene,&#xD;
reach,&#xD;
grip,&#xD;
common daily activities. For each of these categories, participants report amount of difficulty they have in performing two or three specific activities. There are four possible responses for the HAQ questions: without ANY difficulty&#xD;
(0), with SOME difficulty (1), with MUCH difficulty (2) and UNABLE to do (3). Scores for each of the eight categories are calculated. HAQ is calculated by adjusting the score for each of these categories, if necessary, based upon the patient's use of an aid, device, or assistance for that category, totaling the sum of the category scores and dividing by the number of categories answered. HAQ can range from 0 to 3. Higher scores (greater level of difficulty) indicate worse outcome.</description>
        <time_frame>Baseline, End of Treatment Visit (Week 7)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort A - SAN-300 0.5 mg/kg QW</title>
            <description>SAN-300 0.5 mg/kg subcutaneous once weekly for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Cohort B - SAN-300 1.0 mg/kg QW</title>
            <description>SAN-300 1.0 mg/kg subcutaneous once weekly for six weeks</description>
          </group>
          <group group_id="O3">
            <title>Cohort C - SAN-300 2.0 mg/kg QOW</title>
            <description>SAN-300 2.0 mg/kg subcutaneous every other week for six weeks</description>
          </group>
          <group group_id="O4">
            <title>Cohort D - SAN-300 4.0 mg/kg QOW</title>
            <description>SAN-300 4.0 mg/kg subcutaneous once every other week for six weeks</description>
          </group>
          <group group_id="O5">
            <title>Cohort E - SAN-300 4.0 mg/kg QW</title>
            <description>SAN-300 4.0 mg/kg subcutaneous every week for six weeks</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo dosing</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Health Assessment Questionnaire-Disease Index (HAQ-DI)</title>
          <description>HAQ assesses the degree of difficulty a participant has had in accomplishing tasks in eight functional areas, over the previous week.&#xD;
dressing and grooming,&#xD;
rising,&#xD;
eating,&#xD;
walking,&#xD;
hygiene,&#xD;
reach,&#xD;
grip,&#xD;
common daily activities. For each of these categories, participants report amount of difficulty they have in performing two or three specific activities. There are four possible responses for the HAQ questions: without ANY difficulty&#xD;
(0), with SOME difficulty (1), with MUCH difficulty (2) and UNABLE to do (3). Scores for each of the eight categories are calculated. HAQ is calculated by adjusting the score for each of these categories, if necessary, based upon the patient's use of an aid, device, or assistance for that category, totaling the sum of the category scores and dividing by the number of categories answered. HAQ can range from 0 to 3. Higher scores (greater level of difficulty) indicate worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.333" spread="0.335"/>
                    <measurement group_id="O2" value="-0.018" spread="0.064"/>
                    <measurement group_id="O3" value="-0.146" spread="0.060"/>
                    <measurement group_id="O4" value="-0.313" spread="0.313"/>
                    <measurement group_id="O5" value="0.042" spread="0.070"/>
                    <measurement group_id="O6" value="-0.111" spread="0.129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Bone Erosion Detected Using Magnetic Resonance Imaging (MRI) Findings of the Hand and Wrist - Change From Baseline</title>
        <description>Bone Erosion detected by MRI of hand/wrist was scored using the Outcome Measures in Rheumatology Clinical Trials (OMERACT) RA MRI scoring (RAMRIS) system. Bone erosion was scored 0-10, according to the proportion (in increments of 10%) of erosion of articular bone: 0: 0%, 1: 1%-10%, 2: 11%-20%, ……..10: 91%-100%. Higher scores (more erosion) indicate worse outcome.</description>
        <time_frame>Baseline, End of Treatment Visit (Week 7)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort A - SAN-300 0.5 mg/kg QW</title>
            <description>SAN-300 0.5 mg/kg subcutaneous once weekly for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Cohort B - SAN-300 1.0 mg/kg QW</title>
            <description>SAN-300 1.0 mg/kg subcutaneous once weekly for six weeks</description>
          </group>
          <group group_id="O3">
            <title>Cohort C - SAN-300 2.0 mg/kg QOW</title>
            <description>SAN-300 2.0 mg/kg subcutaneous every other week for six weeks</description>
          </group>
          <group group_id="O4">
            <title>Cohort D - SAN-300 4.0 mg/kg QOW</title>
            <description>SAN-300 4.0 mg/kg subcutaneous once every other week for six weeks</description>
          </group>
          <group group_id="O5">
            <title>Cohort E - SAN-300 4.0 mg/kg QW</title>
            <description>SAN-300 4.0 mg/kg subcutaneous every week for six weeks</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo dosing</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Erosion Detected Using Magnetic Resonance Imaging (MRI) Findings of the Hand and Wrist - Change From Baseline</title>
          <description>Bone Erosion detected by MRI of hand/wrist was scored using the Outcome Measures in Rheumatology Clinical Trials (OMERACT) RA MRI scoring (RAMRIS) system. Bone erosion was scored 0-10, according to the proportion (in increments of 10%) of erosion of articular bone: 0: 0%, 1: 1%-10%, 2: 11%-20%, ……..10: 91%-100%. Higher scores (more erosion) indicate worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.73" spread="0.496"/>
                    <measurement group_id="O2" value="0.25" spread="0.214"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0.13" spread="0.125"/>
                    <measurement group_id="O5" value="0.22" spread="0.222"/>
                    <measurement group_id="O6" value="0.13" spread="0.125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data are collected during a 10-week period, which included 6 weeks of treatment and 4 weeks of follow up.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cohort A - SAN-300 0.5 mg/kg QW</title>
          <description>SAN-300 0.5 mg/kg subcutaneous once weekly for six weeks</description>
        </group>
        <group group_id="E2">
          <title>Cohort B - SAN-300 1.0 mg/kg QW</title>
          <description>SAN-300 1.0 mg/kg subcutaneous once weekly for six weeks</description>
        </group>
        <group group_id="E3">
          <title>Cohort C - SAN-300 2.0 mg/kg QOW</title>
          <description>SAN-300 2.0 mg/kg subcutaneous every other week for six weeks</description>
        </group>
        <group group_id="E4">
          <title>Cohort D - SAN-300 4.0 mg/kg QOW</title>
          <description>SAN-300 4.0 mg/kg subcutaneous once every other week for six weeks</description>
        </group>
        <group group_id="E5">
          <title>Cohort E - SAN-300 4.0 mg/kg QW</title>
          <description>SAN-300 4.0 mg/kg subcutaneous every week for six weeks</description>
        </group>
        <group group_id="E6">
          <title>Placebo</title>
          <description>Placebo dosing</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Flank Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrheoa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Mouth Ulcerations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection Site Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection Site Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Pressure Increase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Electrocardiogram Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>VP Clinical Services</name_or_title>
      <organization>Valeant Pharmaceuticals</organization>
      <phone>9089271162</phone>
      <email>christine.hnatko@valeant.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

